FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva Pharmaceuticals Clear Eyes Recall

Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophthalmic s…

Teva Pharmaceuticals USA Inc · Parsippany, NJ

Risk level
Class II
Reported by FDA
Mar 22, 2023
Recall ID
D-0469-2023
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Clear Eyes starting Feb 23, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0469-2023 on Mar 22, 2023. Reason: Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity. Status: Terminated.

Why it was recalled

Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Product description

Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophthalmic solution, USP, 0.2%, Antihistamine, 2.5 mL (0.085 fl oz) bottle, Sterile, Distributed by Medtech Products Inc. Tarrytown, NY 10591, A Prestige Consumer Healthcare company, Made in Israel, UPC 678112000708; NDC 67172-504-01.

Lot numbers, UPCs & expiration codes

Lot #114349, Exp. 05/2023; 117396, Exp. 09/2023; 120128, Exp. 11/2023; 114371, Exp. 06/2023; 123781, Exp. 02/2024.

Where it was sold

Nationwide in the U.S.A.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0469-2023
Classification
Class II
Status
Terminated
Recall initiated
Feb 23, 2023
FDA report date
Mar 22, 2023
Quantity
715,632 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA Inc

Original FDA data

Every field from FDA enforcement report D-0469-2023, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
91757
Address
400 Interpace Pkwy Bldg A
Code information
Lot #114349, Exp. 05/2023; 117396, Exp. 09/2023; 120128, Exp. 11/2023; 114371, Exp. 06/2023; 123781, Exp. 02/2024.
Postal code
07054-1120
Report date
Mar 22, 2023
Product type
Drugs
Recall number
D-0469-2023
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA Inc
Product quantity
715,632 bottles
Termination date
Nov 28, 2023
Reason for recall
Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Clear Eyes, Once Daily, Eye Allergy Itch Relief, olopatadine hydrochloride ophthalmic solution, USP, 0.2%, Antihistamine, 2.5 mL (0.085 fl oz) bottle, Sterile, Distributed by Medtech Products Inc. Tarrytown, NY 10591, A Prestige Consumer Healthcare company, Made in Israel, UPC 678112000708; NDC 67172-504-01.
Distribution pattern
Nationwide in the U.S.A.
Recall initiation date
Feb 23, 2023
Initial firm notification
Letter
Center classification date
Mar 20, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0469-2023, published Mar 22, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls